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Abstract
Intra-abdominal infections are still associated with high rate of morbidity and mortality.
A multidisciplinary approach to the management of patients with intra-abdominal infections may be an important
factor in the quality of care. The presence of a team of health professionals from various disciplines, working in
concert, may improve efficiency, outcome, and the cost of care.
A World Society of Emergency Surgery (WSES) Consensus Conference was held in Bologna on July 2010, during
the 1st congress of the WSES, involving surgeons, infectious disease specialists, pharmacologists, radiologists and
intensivists with the goal of defining recommendations for the early management of intra-abdominal infections.
This document represents the executive summary of the final guidelines approved by the consensus conference.
Introduction
A World Society of Emergency Surgery (WSES) Consen-
sus Conference was held in Bologna on July 2010, during
the 1st congress of the WSES, involving surgeons, infec-
tious disease specialists, pharmacologists, radiologists and
intensivists with the goal of defining recommendations
for the early management of intra-abdominal infections.
This document represents the executive summary of
the final recommendations approved by the consensus
conference.
The Surgical Infection Society and the Infectious Dis-
eases Society of America have recently generated guide-
lines for the diagnosis and management of complicated
intra-abdominal infections on 2010 [1]. IDSA guidelines
represent an important reference for the management of
intra-abdominal infections.
WSES guidelines represent a further contribution on
this debated topic by specialists worldwide. The recom-
mendations are formulated and graded according to the
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) hierarchy of evidence [2,3]
summarized in Table 1.
Principles of sepsis management
Severe sepsis and septic shock are the leading causes of
multiple organ failure and mortality in noncoronary
intensive care units (ICUs) [4,5].
Unfortunately, despite tremendous basic and clinical
research efforts, mortality from septic shock remains
unchanged at greater than 50%.
In an effort to improve sepsis-related mortality, several
organizations have outlined evidence-based guidelines
(EBGs) for the management of severe sepsis and septic
shock [6].
Physicians have known about the existence of sepsis
for centuries.
In 1992, the American College of Chest Physicians/
Society of Critical Care Medicine (ACCP/SCCM) Con-
sensus Committee developed definitions of patients with
sepsis and its related disorders [7].
This Consensus represents the first attempt to create a
universal language for diagnosing and treating sepsis.
Sepsis is defined as systemic inflammatory response
syndrome (SIRS), resulting from infection.
Identifying patients with severe sepsis early and cor-
recting the underlying microvascular dysfunction may
improve patient outcomes. If not corrected, microvascu-
lar dysfunction can lead to global tissue hypoxia, direct
tissue damage, and ultimately, organ failure.
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Systemic inflammatory response syndrome (SIRS)
SIRS is a reference for the complex findings that result
from a systemic activation of the innate immune
response, regardless of cause.
It includes the presence of more than one of the fol-
lowing manifestations:
• Temperature > 100.4°F or < 96.8°F (> 38°C or < 36°C)
• Heart rate > 90 beats/min
• Tachypnea, as manifested by a respiratory rate >
20 breaths/min or hyperventilation, as indicated by a
PaCO2 < 32 mm Hg
• Alteration of white blood cell count > 12,000 cells/
mm3, < 4,000 cells/mm3, or the presence of > 10%
immature neutrophils.
Sepsis
Sepsis is defined by the American College of Chest Phy-
sicians/Society of Critical Care Medicine (ACCP/SCCM)
as SIRS resulting from infection.
Severe sepsis
Severe sepsis is sepsis associated with at least one acute
organ dysfunction, hypoperfusion, or hypotension.
Septic shock
Septic shock occurs when sepsis-induced hypotension
persists despite adequate fluid resuscitation.
Multiple organ dysfunction syndrome (MODS)
MODS includes altered functions of two or more organs
in an acutely ill patient.
Pathophysiology
Abdominal sepsis occurs as result of intra-abdominal
infection.
The pathophysiology of sepsis takes origin from the
outer membrane components of both gram-negative
organisms (lipopolysaccharide [LPS], lipid A, endotoxin)
and gram-positive organisms (lipoteichoic acid, peptido-
glycan). These outer membrane components are able to
bind to the CD14 receptor on the surface of monocytes.
By virtue of the recently described toll-like receptors, a
signal is then transmitted to the cell, leading to the
eventual production of the proinflammatory cytokines,
including tumor necrosis factor (TNF), interleukin 1
(IL-1), IL-6, IL-8, and gamma interferon (IFN-), as well
as other inflammatory mediators such as prostaglandins,
leukotrienes, platelet activation factor, and nitrogen and
Table 1 Grading of recommendations from Guyatt and colleagues [2]
Grade of
recommendation
Clarity of risk/benefit Quality of supporting evidence Implications
1A
Strong
recommendation,
high-quality evidence
Benefits clearly outweigh risk and
burdens, or vice versa
RCTs without important limitations or
overwhelming evidence from observational
studies
Strong recommendation, can
apply to most patients in most
circumstances without reservation
1B
Strong
recommendation,
moderate-quality
evidence
Benefits clearly outweigh risk and
burdens, or vice versa
RCTs with important limitations (inconsistent
results, methodological flaws, indirect or
imprecise) or exceptionally strong evidence from
observational studies
Strong recommendation, can
apply to most patients in most
circumstances without reservation
1C
Strong
recommendation,
low-quality or very
low-quality evidence
Benefits clearly outweigh risk and
burdens, or vice versa
Observational studies or case series Strong recommendation but may
change when higher quality
evidence becomes available
2A
Weak
recommendation,
high-quality evidence
Benefits closely balanced with risks
and burden
RCTs without important limitations or
overwhelming evidence from observational
studies
Weak recommendation, best
action may differ depending on
circumstances or patient or
societal values
2B
Weak
recommendation,
moderate-quality
evidence
Benefits closely balanced with risks
and burden
RCTs with important limitations (inconsistent
results, methodological flaws, indirect or
imprecise) or exceptionally strong evidence from
observational studies
Weak recommendation, best
action may differ depending on
circumstances or patient or
societal values
2C
Weak
recommendation,
Low-quality or very
low-quality evidence
Uncertainty in the estimates of
benefits, risks, and burden; benefits,
risk and burden may be closely
balanced
Observational studies or case series Very weak recommendation; other
alternatives may be equally
reasonable
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oxygen intermediates. Most of these immunological
mediators present multiple biologic effects, play a criti-
cal role in inflammation and immune responses, and
have been recognized as key mediators in the pathogen-
esis of infectious diseases and, more particularly, the
pathophysiologic alterations observed in endotoxic
shock. As a result of the vicious cycle of inflammation,
cardiovascular insufficiency and multiple organ failure
occur and often lead to death [8-10].
Haemodynamic support
Septic shock is primarily maldistributive shock. Its
pathogenesis involves a complex interaction among
pathologic vasodilation, myocardial dysfunction, and
altered blood flow distribution due to the inflammatory
response to infection. It evolves into a progressive
pathophysiological deterioration that culminates in
hypotension poorly responsive to adequate fluid resusci-
tation accompanied by hypoperfusion and organ
dysfunction.
It is associated with three major pathophysiological
effects: vasodilatation, maldistribution of blood flow, and
myocardial depression.
In septic shock, the absolute intravascular volume may
be normal; however, because of acute vasodilatation,
relative hypovolemia occurs. Differently from other
types of shock that are primarily caused by decreasing
intravascular volume (hypovolemic) or decreasing car-
diac output (cardiogenic), a characteristic of septic
shock is the maldistribution of blood flow in the micro-
circulation. In septic shock also myocardial depression
may occur. The relative hypovolemia, myocardial
depression, and maldistribution result in decreased oxy-
gen delivery (DO2) and subsequent tissue hypoxia.
Rivers and coll. [11] demonstrated that a strategy of
early goal-directed therapy (EGDT) decreases the in-
hospital mortality of patients who are taken to the
emergency department in septic shock.
An organized approach to the haemodynamic support
to sepsis includes use of fluid resuscitation, vasopressor
therapy and inotropic therapy.
Patients with severe sepsis and septic shock may pre-
sent ineffective perfusion. Poor tissues perfusion may
cause a global tissue hypoxia, often associated to an ele-
vated serum lactate level. A serum lactate value greater
than 4 mmol/L (36 mg/dL) is correlated with poorer
outcomes, even if hypotension is not yet present. Fluid
resuscitation should be started as early as possible.
According to the Surviving Sepsis Campaign guide-
lines [6] during the first 6 hrs of resuscitation, the goals
of initial resuscitation of sepsis-induced hypoperfusion
should include all of the following as one part of a treat-
ment protocol:
• Central venous pressure 8 to 12 mm Hg
• Mean arterial pressure (MAP) >65 mm Hg
• Urine output >0.5 mL/kg/hr
• Central venous (superior vena cava) or mixed
venous oxygen saturation >70% or >65%, respectively
The early hypovolemic phase of sepsis must be
always treated by providing appropriate high volume
resuscitation.
The Surviving Sepsis Campaign guidelines [6] recom-
mend that fluid challenge in patients with suspected
hypovolemia be started with > = 1000 mL of crystalloids
or 300-500 mL of colloids over 30 mins. More rapid
administration and greater amounts of fluid may be
needed in patients with sepsis-induced tissue
hypoperfusion.
As the volume of distribution is less large for colloids
than for crystalloids, resuscitation with colloids requires
less fluid to achieve the same goals. A colloid equivalent
is an acceptable alternative to crystalloid. Crystalloids
are less expensive [6].
When an appropriate fluid challenge fails, to restore
an adequate arterial pressure and organ perfusion, ther-
apy with vasopressor agents should be started.
Vasopressor drugs maintain adequate blood pressure
and preserve perfusion pressure for optimizing flow in
various organs.
Both norepinephrine and dopamine are the first-line
vasopressor agents to correct hypotension in septic
shock. Both norepinephrine and dopamine can increase
blood pressure in shock states, although norepinephrine
seems to be more powerful. Dopamine may be useful in
patients with compromised cardiac function and cardiac
reserve [12], but norepinephrine is more effective than
dopamine in reversing hypotension in patients with sep-
tic shock. Dopamine has also potentially detrimental
effects on the release of pituitary hormones and espe-
cially prolactin, although the clinical relevance of these
effects is still unclear and can have unintended effects
such as tachyarrhythmias.
Dopamine has different effects based on the doses [13].
A dose of less than 5 μg/kg/min results in vasodila-
tion of renal, mesenteric, and coronary districts. At a
dose of 5-10 μg/kg/min, beta-1-adrenergic effects
increase cardiac contractility and heart rate. At doses
about 10 μg/kg/min, alpha-adrenergic effects lead
to arterial vasoconstriction and increase blood pres-
sure. Its major side effects are tachycardia and
arrhythmogenesis.
The use of renal-dose dopamine in sepsis is a contro-
versial issue. In the past, low-dose dopamine was routi-
nely used because of the possible renal protective
effects. Dopamine at a dose of 2-3 μg/kg/min was
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known to stimulate diuresis by increasing renal blood
flow.
A multicentre, randomised, double-blind, placebo-con-
trolled study about low-dose dopamine in patients with
at least two criteria for the systemic inflammatory
response syndrome and clinical evidence of early renal
dysfunction (oliguria or increase in serum creatinine
concentration), was published on 2000 [14]. Patients
admitted were randomly assigned a continuous intrave-
nous infusion of low-dose dopamine (2 μg/kg/min) or
placebo administered through a central venous catheter.
Administration of low-dose dopamine by continuous
intravenous infusion to critically ill patients at risk of
renal failure did not confer clinically significant protec-
tion from renal dysfunction.
A meta-analysis of literature from 1966 to 2000 for
studies addressing the use of dopamine in the preven-
tion and/or treatment of renal dysfunction was pub-
lished on 2001 [15]. The Authors concluded that the
use of low-dose dopamine for the treatment or preven-
tion of acute renal failure was not justified on the basis
of available evidence.
Norepinephrine is a potent alpha-adrenergic agonist
with minimal beta-adrenergic agonist effects. Norepi-
nephrine can successfully increase blood pressure in
patients who are septic and remain hypotensive follow-
ing fluid resuscitation. Norepinephrine is effective to
treat hypotension in septic shock patients. In many stu-
dies norepinephrine administration at doses 0.01 to 0.3
μg/kg/min has been shown may be effective [16,17].
On 1993 Martin and coll. [18] published a randomized
trial comparing norepinephrine vs dopamine. 32
volume-resuscitated septic patients were given either
dopamine or norepinephrine to achieve and maintain
normal hemodynamic and oxygen transport parameters
for at least 6 h. Dopamine administration was successful
in only 31% of patients, whereas norepinephrine admin-
istration was successful in 93%. Of the 11 patients who
did not respond to dopamine, 10 responded when nore-
pinephrine was added to therapy. Serum lactate levels
were decreased as well, suggesting that norepinephrine
therapy improved tissue oxygenation.
Recently a prospective trial by Patel and coll. com-
pared dopamine to norepinephrine as the initial vaso-
pressor in fluid resuscitated 252 adult patients with
septic shock [19]. If the maximum dose of the initial
vasopressor was unable to maintain the hemodynamic
goal, then fixed dose vasopressin was added to each
regimen. If additional vasopressor support was needed
to achieve the hemodynamic goal, then phenylephrine
was added. In this study dopamine and norepinephrine
were equally effective as initial agents as judged by
28-day mortality rates. However, there were significantly
more cardiac arrhythmias with dopamine treatment.
The Surviving Sepsis Campaign guidelines [6] state
that there is no sufficient evidence to suggest which
agent is better as initial vasopressor in the management
of patients with septic shock.
Phenylephrine is a selective alpha-1 adrenergic recep-
tor agonist primarily used in anesthesia to increase
blood pressure. Although studies are limited [20], its
rapid onset, short duration, and primary vascular effects
make it an interesting agent in the management of
hypotension associated with sepsis, but there are con-
cerns about its potential to reduce cardiac output in
these patients.
Epinephrine is a potent a-adrenergic and b-adrenergic
agent that increases mean arterial pressure by increasing
both cardiac index and peripheral vascular tone. The
chief concern about the use of epinephrine in septic
patients is the potential to decrease regional blood flow,
particularly in the splanchnic circulation. On 2003 De
Backer and coll. [21] published a trial to compare effects
of dopamine, norepinephrine, and epinephrine on the
splanchnic circulation in septic shock. In patients with
severe septic shock, epinephrine administration
increased global oxygen delivery and consumption. It
caused lower absolute and fractional splanchnic blood
flow and lower indocyanine green clearance, validating
the adverse effects of therapy with epinephrine alone on
the splanchnic circulation.
Epinephrine administration can increase blood pres-
sure in patients who are unresponsive to first-line
agents. It increases heart rate, and has the potential to
induce tachyarrhythmias, ischemia, and hypoglycemia.
Because of its effects on splanchnic circulation and its
propensity to increase lactate concentrations, epinephr-
ine has been considered a second-line agent [22].
A large (330 patients) randomized clinical trial pub-
lished on 2007 by Annane and coll. [23] compared ther-
apy with norepinephrine plus dobutamine (whenever
needed) with epinephrine alone in septic shock. There
was no evidence for a difference in efficacy and safety
between epinephrine alone and norepinephrine plus
dobutamine for the management of septic shock.
Vasopressin is a peptide hormone synthesized in the
hypothalamus and is then transported and stored in the
pituitary gland. Vasopressin mediates vasoconstriction
via V1-receptor activation on vascular smooth muscle
and mediates its antidiuretic effect via V2-receptor acti-
vation in the renal collecting duct system. In addition,
vasopressin, at low plasma concentrations, mediates
vasodilation in coronary, cerebral, and pulmonary arter-
ial circulations.
Vasopressin infusion of 0.01 to 0.04 U/min in patients
with septic shock increases plasma vasopressin levels to
those observed in patients with hypotension from other
causes, such as cardiogenic shock. Increased vasopressin
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levels are associated with a lesser need for other vaso-
pressors. Urinary output may increase, and pulmonary
vascular resistance may decrease. Infusions of > 0.04 U/
min may lead to adverse, likely vasoconstriction-
mediated events [24].
A large multicenter, randomized, double-blind trial
comparing vasopressin versus norepinephrine infusion
in patients with septic shock was published on 2008
[25]. A total of 778 patients underwent randomization
(396 patients received vasopressin and 382 norepinephr-
ine) and were included in the analysis. Low-dose vaso-
pressin did not reduce mortality rates as compared with
norepinephrine among patients with septic shock who
were treated with catecholamine vasopressors.
According to the Surviving Sepsis Campaign guide-
lines [6] low doses of vasopressin (0.03 U/min) may be
effective in raising blood pressure in patients refractory
to other vasopressors and may have other potential phy-
siologic benefits. Terlipressin has similar effects but is
long lasting.
Dobutamine is frequently used in septic shock patients
as an inotropic agent to increase cardiac output, stroke
index, and oxygen delivery (Do2). However, the lack of
benefit, and even possible harm, of dobutamine adminis-
tration to increase Do2 to supranormal values in criti-
cally ill patients has raised questions regarding its use in
the treatment of septic shock. Surviving Sepsis Cam-
paign guidelines [6] recommend that a dobutamine infu-
sion be administered in the presence of myocardial
dysfunction as suggested by elevated cardiac filling pres-
sures and low cardiac output.
Early intervention and implementation of evidence-
based guidelines for the management of severe sepsis
and septic shock improve outcomes in patients with
sepsis. However, this is contingent on the early identifi-
cation of sepsis. The early identification of sepsis is chal-
lenging because many of the signs and symptoms of
sepsis are nonspecific. It is therefore necessary to iden-
tify those patients at highest risk for the development of
sepsis and heighten our awareness for the development
of sepsis in this population. In order to document the
incidence of sepsis, assess its risk factors, and determine
its impact on mortality in a general surgery population,
the American College of Surgeons National Surgical
Quality Improvement Project (NSQIP) dataset was ana-
lyzed [4]. The 2005-2006 NSQIP dataset contains pro-
spectively collected clinical data and outcomes on
152.490 patients collected from 121 academic and com-
munity-based hospitals.
The analysis of the 2005-2006 NSQIP dataset identi-
fied 4 major risk factors for the development of sepsis
or septic shock in general surgery patients: (1) age older
than 60 years, (2) need for emergency surgery, (3) pre-
sence of any of the NSQIP comorbidities, and (4) male
sex. These findings emphasized the need for early recog-
nition through aggressive sepsis screening and rapid
implementation of evidence-based interventions for sep-
sis and septic shock in general surgery patients with
these risk factors.
Recently an analysis of 2005-2007 NSQIP dataset
documented the incidence, mortality rate, and risk fac-
tors for sepsis and septic shock compared with pulmon-
ary embolism and myocardial infarction in the general-
surgery population [5]. Of 363.897 general-surgery
patients, sepsis occurred in 8350 (2.3%), septic shock in
5977 (1.6%), pulmonary embolism in 1078 (0.3%), and
myocardial infarction in 615 (0.2%). Thirty-day mortality
rates for each of the groups were 5.4% for sepsis, 33.7%
for septic shock, 9.1% for pulmonary embolism, and
32.0% for myocardial infarction. The septic-shock group
had a greater percentage of patients older than 60 years.
The need for emergency surgery resulted in more cases
of sepsis and septic shock than did elective surgery. The
presence of any comorbidity increased the risk of sepsis
and septic shock 6-fold and increased the 30-day mor-
tality rate 22-fold.
The incidences of sepsis and septic shock exceed those
of pulmonary embolism and myocardial infarction. The
risk factors for mortality included age older than
60 years, the need for emergency surgery, and the pre-
sence of any comorbidity. These findings confirmed the
need for early recognition of patients at risk via aggres-
sive screening and the rapid implementation of
evidence-based guidelines.
Principles of surgical management
Source control encompasses all measures undertaken to
eliminate the source of infection and to control ongoing
contamination.
As a general principle, every established source of
infection should be controlled as soon as possible. The
urgency of intervention is determined by the rapidity of
the evolution of clinical symptoms.
Control of the septic source can be achieved either by
surgical or non surgical means.
Non-surgical interventional procedures imply percuta-
neous drainages of abscesses.
Ultrasound and CT guided percutaneous drainage of
abdominal and extraperitoneal abscesses in selected
patients are safe and effective [26-33].
However surgery is the most important therapeutic
measure to control intra-abdominal infections.
Generally, the choice of the procedure depends on the
anatomical source of infection, on the degree of perito-
neal inflammation, on the generalized septic response
and on the patient’s general conditions.
Surgical source control entails resection or suture of
a diseased or perforated viscus (e.g. diverticular
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perforation, gastroduodenal perforation), removal of
the infected organ (e.g. appendix, gall bladder), debri-
dement of necrotic tissue or resection of ischemic
bowel.
In cases of IAI complicated by septic shock, a single
operation may not be sufficient to achieve source
control, necessitating re-exploration. Three methods
of local mechanical management following initial
laparotomy for source control are currently debated:
open-abdomen, planned re-laparotomy and on-demand
re-laparotomy.
Following removal of infected tissue, attention should
always shift to the restoration of anatomy and function-
ality of the gastrointestinal tract.
Principles of antimicrobial management
Antimicrobial therapy plays an integral role in the man-
agement of intra-abdominal infections, especially in cri-
tical ill patients where empiric antibiotic therapy must
be delivered as early as possible: in fact inadequate anti-
microbial therapy is one of the variables most strongly
associated to unfavorable outcome [6,34].
The initial antibiotic therapy for IAIs is always empiric
because the patient is often critically ill and microbiolo-
gical data (culture and susceptibility results) usually take
at least 48 hours to become fully available.
The decision tree for the antimicrobial management of
intra-abdominal infections depends mainly on three fac-
tors:
• Presumed pathogens involved and risk factors for
major resistance patterns
• Clinical patient’s severity
• Presumed/identified source of infection.
To predict the main pathogens involved and the
related resistance patterns, infections are to be classed
as community or hospital acquired.
During the past 2 decades the incidence of hospital-
acquired infection caused by resistant microorganisms
has significantly risen, probably in relationship with high
level of antibiotic exposure and increasing rate of
patients with one or more predisposing conditions such
as recent exposure to antibiotics, high severity of illness,
advanced age, co-morbidity, degree of organ dysfunc-
tion, low albumin level, poor nutritional status, immu-
nodepression and presence of malignancy.
The major pathogens involved in community-acquired
intra-abdominal infection are Enterobacteriaceae, Strep-
tococcus spp and anaerobes (especially B. fragilis).
Within the healthcare-associated infections, the spec-
trum of microorganism involved is broader, encompass-
ing not only Enterobacteriaceae, Streptococcus spp. and
anaerobes, but also Enterococcus spp and Candida spp.
The data regarding the role of Candida spp are actu-
ally conflicting: in a prospective multicenter epidemiolo-
gical study conducted in 25 French centers, including
more than 330 cases of peritonitis with positive
microbiological cultures, two thirds of the health care-
associated infections were associated to Enterobacteria-
ceae and one third to Enterococcus spp, while the
isolation rate of Candida spp was less than 5% [35].
In contrast, in an observational study involving over
1182 patients with reliable microbiological data, the two
genera of pathogens isolated from more than 25% of
healthcare-associated infections and more commonly
than from community-acquired infections were Entero-
coccus spp (29%) and Candida spp (33%) [36]. Apart
from its epidemiological relevance, the clinical weight of
Candida spp in peritonitis is high, since the isolation of
the yeast from peritoneal fluid proved to be a variable
independently associated to higher morbidity and mor-
tality in a multiple-center, retrospective, case-control
study conducted in critically ill patients admitted to 17
French ICUs [37].
More recently the same group confirmed the high
mortality of candidal peritonitis (38%) in a prospective
survey related on 93 patients admitted to ICU [38].
Enterococci are frequently responsible for hospital-
acquired IAIs. During the past 2 decades the incidence
of hospital-acquired enterococcal infection has signifi-
cantly risen, probably in relationship with high level of
antibiotic exposure and increasing number of patients
with variable levels of immunosuppresion. In the afore-
mentioned French survey, the prevalence of enterococcal
isolation was significantly higher in the nosocomial cases
of peritonitis and a significant increased incidence of
fatal cases of peritonitis with positive cultures for enter-
ococci was reported (20% versus 9% - p < 0.003) [35].
The threat of antimicrobial resistance has been identi-
fied as one of the major challenges in the management
of intra-abdominal infections. The emergence of multi-
drug-resistant bacteria and the scanty pipeline of new
antibiotics to fight them are, as of today, a concern
especially for gram negative microorganisms, as high-
lighted in a recent report from the European Antimicro-
bial Resistance Surveillance System [39].
Hospital-acquired IAIs are commonly caused by more
resistant bacteria, although the level of resistance is sig-
nificant also in the community acquired infections.
The Study for Monitoring Antimicrobial Resistance
Trends (SMART) program has been monitoring the
activity of antibiotics against aerobic Gram-negative
intra-abdominal infections. Hawser and coll. [40]
reported susceptibility levels of key intra-abdominal
pathogens in Europe for 2008, and showed that
the options for effective empirical therapy of intra-
abdominal infection have significantly reduced.
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Coque and coll. highlighted the growing threat posed
by increasing prevalence of extended-spectrum beta-lac-
tamase (ESBL) producing Enterobacteriaceae all over
Europe, even in countries traditionally showing low pre-
valence rates of resistance [41]. Increase of this resis-
tance pattern has led to a progressive expansion of
carbapenems use, because this class of antibiotics was
traditionally considered the last resort for managing
ESBL producers Enterobacteriaceae.
The inevitably increased carbapenem consumption has
been associated to increasing carbapenemase production
among Enterobacteriaceae. The recent rapid spread of
serine carbapenemase in Klebsiella pneumoniae (KPC) is
now an additional major threat for antimicrobial therapy
in hospitals worldwide, and stresses the concept that the
use of carbapenems must be mandatorily optimized in
terms of indication and exposure [42].
Also Acinetobacter spp have worldwide shown similar
alarming rates of increasing resistance to antibiotics.
Today, Carbapenem-resistant A. baumannii-producing
oxacillinases retaining susceptibility to only colistin and
tigecycline is an ominous reality in hospitals worldwide
and compounding this problem is the paucity of new
antibiotics under development to address it [43].
In hospital acquired IAIs also P. aeruginosa plays an
important - although less critical than in other settings -
role. The high intrinsic antibiotic resistance of this
pathogen, together with its extraordinary capacity for
acquiring additional resistances through chromosomal
mutations, should be always taken into consideration.
Among multidrug resistant Gram positive bacteria,
Enterococci remain a challenge despite the availability of
large number of antimicrobial agents theoretically active
against this species. The clinical management of entero-
coccal infection remains challenging, mainly because no
single agent could be anticipated to exert strong bacteri-
cidal activity against them.
Clinical patient’s severity
This choice of the antimicrobial regimen poses serious
problems for the management of critically ill patients. In
patients with severe sepsis or septic shock an early cor-
rect empirical antimicrobial therapy has a significant
impact on the outcome, independently by the site of
infection [44].
This data confirm the results of Riché and coll. who
demonstrated, in a prospective observational study
involving 180 consecutive patients with secondary gen-
eralized peritonitis, a significantly higher mortality rate
in septic shock (35 versus 8% for patients without
shock) [45].
Recent international guidelines for the management of
severe sepsis and septic shock (Surviving Sepsis Cam-
paign) [6] recommend intravenous antibiotics within the
first hour after severe sepsis and septic shock are recog-
nized, use of broad-spectrum agents with good penetra-
tion into the presumed site of infection, and
reassessment of the antimicrobial regimen daily to opti-
mize efficacy, prevent resistance, avoid toxicity and
minimize costs [6]. Full adherence to these recommen-
dations requires that clinicians, in order to optimize
antibiotic therapy in critically ill patients, be aware that
it is not sufficient to make the correct choice on the
basis of the anti-biogram or of a correct epidemiological
evaluation of risk factor for microorganisms and resis-
tance patterns, but it is also mandatory to implement
timely administration of the right dose on the right
schedule, according to the pathophysiological and
immunological status of the patient and to the pharma-
cokinetics properties of the chosen drugs [46].
This concept is correct not only from a clinical point
of view; in fact sub-optimal plasma levels of antimicro-
bials and/or suboptimal exposure to antimicrobials in
the infection site represent the best condition to favor
the emergence of resistant strains, with a consequent
higher probability of therapeutic failure and increased
human and social costs.
For example, in critically ill patients, higher-than-stan-
dard loading doses of b-lactams, aminoglycosides or gly-
copeptides should be administered to ensure optimal
exposure at the infection site independently of the
patient’s renal function [47-49].
For lipophilic antibiotics such as fluoroquinolones and
tetracyclines, the ‘dilution effect’ in the extracellular
fluids during severe sepsis may be mitigated by the
rapid redistribution of the drug from the intracellular
compartment to the interstitium. In contrast to what
happens with hydrophilic antimicrobials, standard
dosages of lipophilic antimicrobials may frequently
ensure adequate loading even in patients with severe
sepsis or septic shock [47].
Once appropriate initial loading is achieved, daily reas-
sessment of the antimicrobial regimen is warranted,
because the pathophysiological changes that may occur
could significantly affect drug disposition in the critically
ill patients.
Conversely, it is less evident that higher than standard
dosages of renally excreted drugs may be needed for
optimal exposure in patients with glomerular hyperfil-
tration [47].
Therefore, selecting higher dosages and/or alternative
dosing regimens focused on maximizing the pharmaco-
dynamics of antimicrobials might be worthwhile, with
the intent being to increase clinical cure rates among
critically ill patients.
Indeed, different approaches should be pursued
according to the mechanism of antimicrobial activity
exhibited by each antimicrobial. Two patterns of
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bactericidal activity have been identified: time-dependent
activity (where the time that the plasma concentration
persists above the MIC of the etiological agent is con-
sidered the major determinant for efficacy) and concen-
tration-dependent activity (where the efficacy is mainly
related to the plasma peak concentration in relation to
the MIC of the microorganism). In addition, these
agents show an associated concentration-dependent
post-antibiotic effect, and bactericidal action continues
for a period of time after the antibiotic level falls below
the MIC [50].
Beta-lactams, glycopeptides, oxazolidinones, and azoles
exhibit time-dependent activity: the shorter the drug
elimination half-life, the more frequent the daily dose
fractioning must be. For these drugs the employ of
intravenous continuous infusion, which ensures the
highest steady-state concentration under the same total
daily dosage, may be the most effective way of maximiz-
ing pharmacodynamic exposure [51-54].
On the other hand, quinolones, daptomycin, tigecy-
cline, aminoglycosides, polienes and echionocandins
exhibit concentration-dependent activity; therefore the
entire daily dose should be administered in a once daily
way (or with the lowest possible number of daily admin-
istrations) with the intent of achieving the highest peak
plasma level. The use of extended-interval aminoglyco-
side dosing strategies for the treatment of moderate-to-
severe infections encountered in critically ill surgical
patients [55,56].
Classifications
Intra-abdominal infections (IAIs) include a lot of patho-
logical conditions, ranging from uncomplicated appendi-
citis to faecal peritonitis.
From a clinical viewpoint IAIs are classified into
uncomplicated and complicated [57].
In uncomplicated IAIs the infectious process only
involves a single organ and does not proceed to the
peritoneum.
In complicated IAIs, the infectious process proceeds
beyond the organ, and causes either localized peritonitis
(intra-abdominal abscess), or diffuse peritonitis.
Peritonitis is classified into primary, secondary or ter-
tiary peritonitis [58].
Primary peritonitis is a diffused bacterial infection
without loss of integrity of the gastrointestinal tract. It is
rare. It mainly occurs in infancy and early childhood
and in cirrhotic patients.
Secondary peritonitis, the most common form of peri-
tonitis, is acute peritoneal infection resulting from loss
of integrity of the gastrointestinal tract or from infected
viscera. It is caused by perforation of the gastrointestinal
tract (e.g. perforated duodenal ulcer), by direct invasion
from infected intra-abdominal viscera (e.g. gangrenous
appendicitis). Anastomotic dehiscences are common
causes of peritonitis in the postoperative period.
Tertiary peritonitis is defined as peritonitis that per-
sists after more than one failed source control procedure
[59].
Intra-abdominal infections are also classified into
community-acquired intra-abdominal infections (CA-
IAIs) and healthcare-acquired intra-abdominal infections
(HA-IAIs). CA-IAIs are acquired in community, whereas
HA-IAIs develop in hospitalized patients or residents of
long-term care facilities. They are characterized by
increased mortality because of both underlying patient
health status and increased likelihood of infection
caused by multi drugs resistant organisms [59].
Moreover, in the classification of IAIs should be man-
datory to introduce a grading of clinical severity, well
represented by the sepsis definitions.
The updated sepsis definition is based on several clini-
cal and bioumoral variables [60].
As is well demonstrated, there is an increased risk of
death moving from the sepsis status to that of severe
sepsis [61], and it appears reasonable to assume the lat-
ter as the breakpoint between a condition of clinical sta-
bility and a critically ill patient.
Diagnosis
Accurate physical examination and laboratory studies
are able to identify most patients with intra-abdominal
sepsis undergoing immediate laparotomy (1 C).
In the patient with abdominal sepsis early detection
and treatment is essential to minimize complications [7].
Complicated intra-abdominal infections diagnosis is
mainly a clinical diagnosis.
Abdominal pain may be acute or insidious.
Hypotension and hypoperfusion signs such as lactic
acidosis, oliguria, and acute alteration of mental status
are indicative of evolution to severe sepsis [7].
Abdominal rigidity suggests peritonitis and the need
for urgent laparotomy.
Plain films of the abdomen are often the first imaging
studies obtained in patients presenting with intra-
abdominal infections.
Upright films are useful for identifying free air under
the diaphragm (most often on the right) as an indication
of a perforated viscus.
In adult stable patients not undergoing immediate
laparotomy, computerized tomography (CT) is the
imaging modality of choice for intra-abdominal
infections in adults (recommendation 2 B).
Especially in children, the radiation associated with
CT, should be always be considered.
In unstable patients not undergoing immediate
laparotomy who may not undergo studies requiring
them to leave the ICU or emergency room, then
Sartelli et al. World Journal of Emergency Surgery 2011, 6:2
http://www.wjes.org/content/6/1/2
Page 8 of 29
ultrasound is the imaging modality of choice (recom-
mendation 2 B).
When patients are stable, computerized tomography
(CT) is the imaging modality of choice for most intra-
abdominal processes [62,63].
Computed tomography (CT) of the abdomen and pel-
vis, when it is possible to perform, remains the diagnos-
tic study of choice for intra-abdominal infections. CT
should be performed with enteral and intravenous con-
trast [64].
Unstable Patients may not undergo studies that
require trips away from the ICU or emergency depart-
ment. In these patients intra-abdominal septic source
may be detected by ultrasound (US) [65].
In experienced hands, the ultrasound can reliably
diagnose most acute abdominal conditions in most
patients.
Abdominal ultrasound has the advantage of being por-
table and may be helpful in the evaluation of right upper
quadrant (eg, perihepatic abscess, cholecystitis, pancrea-
titis), right lower quadrant, and pelvic pathology (eg,
appendicitis, tubo-ovarian abscess, Douglas abscess), but
the examination is sometimes limited because of patient
discomfort, abdominal distension, and bowel gas inter-
ference [66].
The value of both CT and US in the diagnostic work-
up for intra-abdominal infections has been fully studied
in relation to acute appendicitis. A meta-analysis by
Doria and coll. evaluated the diagnostic performance of
ultrasonography (US) and computed tomography (CT)
for the diagnosis of appendicitis in pediatric and adult
populations. This meta-analysis found that pooled sensi-
tivity and specificity for diagnosis of appendicitis in chil-
dren were 88% and 94%, respectively, for ultrasound
studies and 94% and 95%, respectively, for CT studies.
Pooled sensitivity and specificity for diagnosis in adults
were 83% and 93%, respectively, for ultrasound studies
and 94% and 94%, respectively, for CT studies.
From the diagnostic performance perspective, CT has
a significantly higher sensitivity than US in studies of
children and adults; from the safety perspective, how-
ever, the radiation associated with CT, especially in chil-
dren, should be always considered [67].
Treatment
Schematically intra-abdominal infections have been
divided into three groups.
• Community acquired extrabiliary intra-abdominal
infections
• Community acquired biliary intra-abdominal
infections
• Hospital acquired intra-abdominal infections
Extra-Biliary Community-Acquired Intra-
Abdominal Infections
Source control
Gastro-duodenal perforation
In the case of a perforated peptic ulcer, surgery is
the treatment of choice. In selected cases (pts
younger than 70 ys old, no shock, no peritonitis,
lack of spillage of the water-soluble contrast
medium at gastroduodenogram) non-operative man-
agement may be attempted. After initial non opera-
tive management, no improvement of conditions
within 24 hours is indication to surgery (Recom-
mendation 1 A).
In case of perforated peptic ulcer, surgery is consid-
ered the standard method of source control [68,69], also
because postoperative mortality and morbidity rates
have improved significantly [70].
Studies about the natural history of gastroduodenal
ulcer perforation between the second half of 19th and
the first half of 20th century [71,72] reported that per-
forations of the stomach were sealed by adhesions to
the surrounding viscera preventing leakage from the sto-
mach into the peritoneum.
In 1946, Taylor presented the first series of successful
outcome of patients with perforated peptic ulcer conser-
vatively treated [73]. Nowadays conservative treatment,
also known as “Taylor method”, consists of naso-gastric
aspiration, antibiotics, intravenous fluids and H. pylori
eradication therapy [74-76].
Patients older than 70 years old are significantly less
like to respond to conservative treatment than younger
patients [77]; also major medical illness, shock on
admission and longstanding perforation (>24 hrs) are
significantly associated with higher mortality rate in case
of perforated peptic ulcer [78-80].
During non operative management, rapid deterioration
or no improvement of clinical conditions within
24 hours from starting treatment are absolute indica-
tions to surgical treatment [81,82].
Finally, delaying the time point of operation beyond
12 h after the onset of clinical symptoms will worsen
the outcome in perforated peptic ulcer [83].
Simple closure with or without omental patch is an
effective and safe operation in case of small perfo-
rated ulcers (<2 cm). H. pylori status should be
determined when the patients recover from the acute
episode and the bacterium should be eradicated in
those who are infected. (Recommendation 1 A).
In case of large perforated ulcers, concomitant
severe bleeding or stricture, resective gastro-duodenal
surgery may be required. The need for resection is
established by surgeon based on intraoperative find-
ings (Recommendation 1 B).
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In case of small perforated gastroduodenal peptic
ulcer, no significant differences in immediate postopera-
tive course were reported after simple closure or defini-
tive surgery [84-87].
Different suture techniques for simple closure of
the perforation were described: simple closure by
interrupted sutures [88] simple closure by interrupted
sutures covered with pedicled omentoplasty, closure
with a pedicled omental plug drawn into the perfora-
tion [89] and finally closure with a free omental
patch [90].
Many patients in the published studies received omen-
tal patch repair rather than simple suture, but there was
nearly no comparative evidence available to decide
which repair technique is superior. A trial by Lau and
coll. compared patch repair with fibrin sealing without
finding any differences [91].
After closure alone, long term recurrence rate of pep-
tic ulcer was significantly higher than after definitive
surgery [92-95].
Eradication of Helicobacter pylori after simple closure
and omental patch for perforated duodenal and gastric
ulcers prevents recurrence.
To determine whether eradication of Helicobacter
pylori could reduce the risk of ulcer recurrence after
simple closure of perforated duodenal ulcer, a rando-
mized controlled trial was conducted by Ng and coll.
[96]. After 1 year, ulcer relapse was significantly less
common in patients treated with anti-Helicobacter ther-
apy than in those who received omeprazole alone (4.8%
vs. 38.1%).
The first two cases of primary gastric resection for
ulcer perforation were described by von Haberer as
early in 1919 [97].
The method was used extensively for several decades
but it is now rarely used for treatment of ulcer perfora-
tion. The role of resectional surgery in case of perfo-
rated peptic gastroduodenal disease is not well
established; many reports advocate gastrectomy only in
selected patients, in case of large gastric perforations,
with concomitant severe bleeding or stricture [98-101].
Laparoscopic repair of perforated peptic ulcer is
safe and effective in centers with experience (Recom-
mendation 1 A).
The p.o. outcome of laparoscopic approach does not
significantly differ from that of open surgery, except for
lower analgesic p.o. request.
In all studies the patients had small ulcers (mean dia-
meter 1 cm) and all patients received simple suture,
mostly with omental patch, or sutureless repair.
No experience was reported with emergency laparo-
scopic resection or laparoscopic repair of large ulcers.
One systematic review [102], one meta-analysis [103]
and three randomized controlled trials [104-106]
comparing open and laparoscopic approach to gastro-
duodenal perforations were published. The postoperative
course after laparoscopic repair did not significantly dif-
fer from that of open repair, except for lower analgesic
request.
Biopsy and frozen section should be performed in
all gastric perforations when a pathologist is avail-
able (Recommendation 2 C)
If a patient has a curable tumor and acceptable
general conditions (no shock, localized peritonitis,
no comorbidities) the treatment of choice is gastrect-
omy (total or sub-total) with D2 lymph-node dissec-
tion; with poor general conditions and curable tumor
is indicated a two-stage radical gastrectomy (first
step simple repair and gastrectomy in a secondary
elective intervention); with poor general conditions
or non-curable tumor is indicated simple repair
(Recommendation 2 C).
Treatment of choice of perforated gastric cancer is
surgery. In most instances gastric carcinoma is not sus-
pected as the cause of perforation prior to emergency
laparotomy, and the diagnosis of malignancy is often
made only by intraoperative or postoperative pathologic
examination. The treatment should aim to manage both
the emergency condition of peritonitis and the oncologic
technical aspects of surgery.
Perforation alone does not significantly affect long
term survival after gastrectomy [107], differed resection
(i.e. two stage radical gastrectomy) does not affect long
term outcome [108,109].
The presence of preoperative shock seems to be the
most important negative prognostic factor for immedi-
ate postoperative survival after surgery for perforated
gastric cancer [110].
Therefore, patients who have perforated gastric cancer
should undergo appropriate gastric resection in spite of
concurrent peritonitis unless the patient is hemodyna-
mically unstable or has unresectable cancer [111-114].
Small bowel perforations
In patients with small bowel perforations, surgery is
the treatment of choice. (Recommendation 1 A).
In case of small perforations, primary repair is pre-
ferable; when resection is required, the technique of
anastomosis does not influence postoperative mortal-
ity or morbidity rates. (Recommendation 2 B).
Laparoscopic approach should be performed by a
laparoscopically experienced surgeon in selected
institutions (Recommendation 2 C).
Primary repair of perforated bowel is preferable to
resection and anastomosis because it carries a lower
complication rate [115,116] even if the better outcome
may reflect the limited tissue injury in these patients.
Primary repair should not be performed in patients who
have malignant lesions, necrotic bowel, perforations
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associated with mesenteric vascular injuries, or multiple
contiguous perforations [117].
When resection is required, the entire diseased seg-
ment is resected, leaving healthy, well perfused ends for
anastomosis. The technique for the enteroenterostomy,
whether stapled or hand-sewn, seems to have little
impact on the anastomotic complication rate [118,119].
Primary bowel anastomosis must be considered cau-
tiously in the setting of gross purulent or feculent peri-
tonitis because of a high rate of serious complications
[120,121]. Laparoscopic management of small bowel
perforations was reported [122] but there was no com-
parative study with open surgery.
Acute Appendicitis
Acute appendicitis is the most common intra-abdominal
condition requiring emergency surgery.
The Surgical Infection Society and the Infectious Dis-
eases Society of America have generated guidelines for
the management and treatment of complicated intra-
abdominal infections on 2010 [1].
Operative intervention for acute, non-perforated
appendicitis is the treatment of choice. Non-operative
management of patients with acute, non-perforated
appendicitis can be considered if there is a marked
improvement in the patient’s condition prior to
operation (Recommendation 1 A).
Antibiotic treatment has been shown to be effective in
treating selected patients with acute appendicitis. Three
randomized controlled trials (RCTs) have compared the
efficacy of antibiotic therapy alone with that of surgery
for acute appendicitis [123-125]. A meta-analysis of
these RCTs concluded that while antibiotics may be use-
ful as primary treatment for selected patients, antibiotics
are unlikely to replace appendectomy at present [126].
Selection bias and crossover to surgery in the RCTs sug-
gest that appendectomy is still the gold standard therapy
for acute appendicitis. A support for a less emergent
approach comes from clinical trials analyzing time to
perforation, which indicate this to be an unusual early
event [127,128].
Both open and laparoscopic approaches to appen-
dectomy are appropriate (Recommendation 1 A).
A systematic review that included 45 randomized
trials compared the diagnostic and therapeutic effects of
laparoscopic and conventional open appendectomy in
the treatment of suspected acute appendicitis [129]. The
most consistent findings were an approximately 50%
reduction in wound infections but a threefold increase
in intra-abdominal abscesses in the laparoscopic appen-
dectomy group. However, subsequently, two large stu-
dies have shown that patients undergoing a laparoscopic
technique were more likely to be readmitted within
28 days of surgery [130] and that the risk for a compli-
cation was higher in the laparoscopic appendectomy
group with uncomplicated appendicitis [131]. Taken
together, open appendectomy may be preferred,
although laparoscopic appendectomy is useful in
selected subgroups of patients. Use of either approach
should be decided by the surgeon’s expertise. The
laparoscopic approach is useful for obese patients,
elderly patients and patients whose diagnosis is uncer-
tain, especially women of childbearing age.
Patients with perforated appendicitis should
undergo urgent intervention (Recommendation 1 C).
Patients with a periappendiceal abscess can be
managed with percutaneous image-guided drainage.
Appendectomy is generally deferred in such patients
(Recommendation 1 A).
If imaging studies demonstrate a periappendiceal
abscess, CT- or ultrasound-guided percutaneous drai-
nage can often be performed. Percutaneous drainage
with or without interval appendectomy to treat periap-
pendiceal abscess results in fewer complications and
shorter overall length of stay [132-134].
The use of interval appendectomy after percuta-
neous abscess drainage or non-operative manage-
ment of perforated appendicitis is controversial
(Recommendation 2 C).
A survey using a postal questionnaire showed that
53% of surgeons performed routine interval appendect-
omy because they worried about recurrence [135]. How-
ever, the recurrence rate of appendicitis (10%-25%) and
the complication rate of interval appendectomy (23%)
are similar [135,136]. It was evident that the chances of
missing malignancy are low and thorough investigation
is better than interval appendectomy in detecting colo-
nic cancer. These studies support the view that interval
appendectomy is unnecessary in 75-90% cases.
Acute diverticulitis
Several major medical organizations, such as The Amer-
ican Society of Colon and Rectal Surgeons, The Society
for Surgery of the Alimentary Tract, The American Col-
lege of Gastroenterology, European Association of Endo-
scopic Surgeons, have proposed recommendations
[137-141]. The practice parameters published by The
American Society of Colon and Rectal Surgeons on
2006 are particularly useful [137]. The recommendations
written here are generally consistent with them.
Complicated diverticulitis is defined as acute diverticu-
litis accompanied by abscess, fistula, obstruction, or free
intra-abdominal perforation. Approximately 25% of
patients diagnosed with diverticulitis for the first time
present with complicated diverticulitis. Uncomplicated
diverticulitis, accounting for 75% of cases, refers to
diverticulitis without the complications noted above.
Hinchey Classification is used to describe perforations
of the colon due to diverticulitis [142]. The classification
is I-IV: Hinchey stage I - localized abscess (para-colonic),
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Hinchey stage II - pelvic abscess, Hinchey stage III -
purulent peritonitis (the presence of pus in the abdom-
inal cavity), and Hinchey stage IV - fecal peritonitis.
Non-operative treatment, with bowel rest and anti-
biotics, is suggested in patients with uncomplicated
diverticulitis (Recommendation 1 C).
Conservative treatment of acute uncomplicated
diverticulitis is successful in 70 to 100 percent of
patients [137]. Uncomplicated diverticulitis may be
managed as an outpatient (dietary modification and
oral antibiotics) for those without appreciable fever,
excessive vomiting, or marked peritonitis, as long as
there is the opportunity for follow-up. The patient
should be able to take liquids and antibiotics by
mouth. Hospitalization is indicated if the patient is
unable to take liquids or has severe pain, or if symp-
toms fail to improve despite adequate outpatient ther-
apy. Antibiotics should be selected to treat the most
common bacteria found in the colon: gram-negative
rods and anaerobic bacteria [143]. Non-operative treat-
ment will resolve acute diverticulitis in 85 percent of
patients, but approximately one-third will have a recur-
rent attack often within one year [144].
The decision to recommend elective sigmoid
colectomy after recovery from acute diverticulitis
should be made on a case-by-case basis (Recommen-
dation 1 C).
The overall rate of recurrence appears to be approxi-
mately 10 to 30% within a decade after a first documen-
ted attack and that the majority of patients who have a
single episode of diverticulitis will not have another
[145]. In one report involving an average follow-up of
9 years with 2551 patients whose initial episode of diver-
ticulitis was treated successfully without surgery, only
13% had recurrent attacks and only 7% required colect-
omy [146]. These observations imply that routine elec-
tive colectomy is probably unwarranted if the disease is
successfully managed on initial presentation and that
surgical treatment should be limited to patients whose
symptoms persist despite conservative therapy [147].
Thus, continued observation may be appropriate for
most patients who have repeated attacks of uncompli-
cated diverticulitis.
Systemic antibiotic treatment alone is usually the
most appropriate treatment for patients with a small
(<4 cm in diameter) diverticular abscess and image
guided percutaneous drainage is for those with a large
(>4 cm in diameter) one (Recommendation 2 B).
For patients in whom diverticulitis is complicated by
peridiverticular abscess formation, the size of the abscess
is an important determinant of the need for percutaneous
drainage [145]. Many patients who have small pericolic
abscesses (4 cm or less in diameter) without peritonitis
(Hinchey stage 1) can be treated conservatively with
bowel rest and broad-spectrum antibiotics [148]. For
patients with peridiverticular abscesses that are larger
than 4 cm in diameter (Hinchey stage 2), observational
studies indicate that CT-guided percutaneous drainage
can be beneficial [149-160]. This procedure typically
eliminates or reduces the size of the abscess
[148,151,152], with a reduction in pain, resolution of leu-
kocytosis, and defervescence usually seen within several
days [153]. Percutaneous drainage may allow for elective
rather than emergency surgery, increasing the likelihood
of a successful one-stage procedure. Patients whose
abscess cavities contain gross feculent material tend to
respond poorly, and early surgical intervention is usually
required.
Elective colon resection should typically be advised
if an episode of complicated diverticulitis is treated
non-operatively (Recommendation 2 C).
After percutaneous drainage of a diverticular abscess,
a later colectomy usually should be planned, because
41 percent of patients will otherwise develop severe
recurrent sepsis [154]. Some, but not all, retrospective
studies suggest that the number of recurrences is asso-
ciated with the chance that emergency surgery will be
required at some point in the future [155].
The resection should be carried proximally to the
compliant bowel and extend distally to the upper
rectum (Recommendation 1 C).
It is usually sufficient to remove only the most
severely affected segment; however, the proximal margin
of resection should be in an area of pliable colon with-
out hypertrophy or inflammation [137]. Not all of the
diverticula-bearing colon must be removed. Usually a
sigmoid colectomy will suffice; however, occasionally the
proximal resection margin must extend well into the
descending colon or to the left transverse colon. Distally,
the margin of resection should be where the taenia coli
splay out onto the upper rectum. After sigmoid colect-
omy for diverticulitis, an important predictor of recur-
rent diverticulitis is a colosigmoid rather than a
colorectal anastomosis [156,157].
When a colectomy for diverticular disease is per-
formed, a laparoscopic approach is appropriate in
selected patients (Recommendation 1 B).
Laparoscopic colectomy may have advantages over
open laparotomy, including less pain, smaller scar, and
shorter recovery [137]. There is no increase in early or
late complications [158,159]. Cost and outcome are
comparable to open resection [160]. Laparoscopic sur-
gery is acceptable in the elderly [161] and seems to be
safe in selected patients with complicated disease [162].
Urgent operation is required for patients with dif-
fuse peritonitis or for those who fail non-operative
management of acute diverticulitis (Recommenda-
tion 1 B).
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If a patient presents with severe or diffuse peritonitis,
emergency colon resection is necessary. Also, if sepsis
does not improve with inpatient conservative treatment
of acute diverticulitis or after percutaneous drainage,
surgery is indicated [137]. Immunosuppressed or immu-
nocompromised patients are more likely to present with
perforation or fail medical management, so a lower
threshold for urgent or elective surgery should apply to
them [163]. The source control of diffuse peritonitis is
discussed together in the next topic of large bowel
perforations.
Large bowel perforations
No practice guideline has been proposed for the source
control of large bowel perforation.
Causes of large bowel perforations include (1)
penetrating foreign body perforation, (2) extrinsic
bowel obstruction, (3) intrinsic bowel obstruction,
(4) direct loss of bowel wall integrity without for-
eign body perforation, (5) intestinal ischemia, and
(6) infection.
The principles of source control include: control of
the site of perforation, evacuation of contamination,
debridement of necrotic tissue, and re-establishment
of functional anatomy. Many patients who have large
bowel perforations develop sepsis with accompanying
hemodynamic compromise, hypothermia, acidosis,
and a coagulopathy [164]. These patients require
rapid resuscitation and rapid surgery. The standard
approach is known as damage control surgery. The
goal is to rapidly obtain source control and perito-
neal toilet without prolonging the surgery to restore
functional anatomy or extensively mobilize tissues
[165].
The decision whether to perform a proximal diverting
procedure is based on the surgeon’s assessment of the
risks of anastomotic breakdown and other complications
such as the patient’s nutritional status, the quality of the
tissues, the amount of bowel contamination, the extent
of blood loss, and the intraoperative stability of the
patient’s condition [135,166].
Hartmann’s procedure may be performed for the
treatment of large bowel perforations (Recommenda-
tion 2 C).
Two-stage procedures are typically used in emergency
situations with fecal peritonitis and in most cases with
purulent peritonitis. A common approach is the Hart-
mann’s procedure, which involves resection of the dis-
eased colon, an end-colostomy, and creation of a rectal
stump; this is followed by colostomy closure several
months later [167,168]. Reversal of Hartmann’s proce-
dure is also associated with substantial morbidity and
even mortality [169]. It is well known that patients with
stomas may face both physical and psychological diffi-
culties [170,171].
Primary anastomosis with or without proximal
diverting stoma may be performed in selected
patients (Recommendation 2 C).
It appears that resection and primary anastomosis,
with or without proximal diverting stoma (colostomy or
ileostomy), can be safely undertaken in selected patients
who have phlegmons, abscess formation with localized
peritonitis, diffuse purulent peritonitis, obstruction, or
fistula formation [145,166,172,173]. Although data are
not available from randomized trials, observational
studies that include matched patients suggest similar
overall mortality rates and lower risks of wound infec-
tion and postoperative abscess formation with a one-
stage approach [168]. On-table colonic lavage may also
be considered [174].
Antimicrobial therapy for extra-biliary community-
acquired IAIs
Once the diagnosis of intra-abdominal infection is sus-
pected, it is necessary to begin empiric antimicrobial
therapy.
However routine use of antimicrobial therapy is not
appropriate for all patients with intra-abdominal
infections.
In uncomplicated IAIs, when the focus of infection is
treated effectively by surgical excision of the involved
tissue, the administration of antibiotics is unnecessary
beyond prophylaxis [175].
In complicated IAIs, when infectious process proceeds
beyond the organ, causing either localized peritonitis
(intra-abdominal abscess), or diffuse peritonitis antimi-
crobial therapy is mandatory.
The choice of antimicrobial regimen depends on the
source of intra-abdominal infection, risk factors for
specific microorganisms and resistance patterns and
clinical patient’s condition (Recommendation 1 C).
The principles of empiric antibiotic treatment should
be defined according to the most frequently isolated
germs, always taking into consideration the local trend
of antibiotic resistance.
The major pathogens involved in community-acquired
IAIs are Enterobacteriaceae, streptococci and anaerobes.
The main resistance problem is represented by ESBL
producers Enterobacteriaceae, even today frequently
found in community acquired infections.
Many factors can raise the risk of selection of ESBL
but prior exposition to antibiotics (mainly third genera-
tion cephalosporins) and comorbidities that make fre-
quent the exposure of patients to multiple antibiotic
treatments, are the most significant [1,176,177].
Many others factors can contribute to the severity of an
intra-abdominal infection and to a patient’s risk for a poor
outcome, like patient age, underlying co-morbidities,
extent of infection, nutritional status and the success of
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initial source control procedures. Dividing patients
with intra-abdominal infections into lower and higher
risk categories is not always simple, but attempting to
assess a patient’s risk of treatment failure is essential
to optimize a treatment plan. In this context adding a
standardized evaluation of the clinical condition,
represented by the sepsis grading, may be extremely
helpful.
In fact in critically ill patients the possibility that the
normal flora may be modified and that the IAI could be
caused by several unexpected pathogens and by more
resistant flora must be considered. In these patients
antimicrobial regimens with broader spectrum of activity
are recommended.
Therefore in a stable and low risk patient a simpler
antibiotic choice, not including ESBL in the spectrum of
activity is correct, while in critical and high risk patients
any antibiotic regimen must take into account the risk
of ESBL.
The available therapeutic options for the treatment of
ESBL-associated infections are limited by drug resistance
conferred by the ESBLs. The frequently observed
co-resistances include various antibiotic classes (fluoro-
quinolones, aminoglycosides, tetracyclines, and tri-
methoprim/sulfamethoxazole). Carbapenems, stable
against hydrolyzing activity of ESBLs, are considered as
the drug of choice for the treatment of these infections.
Tigecycline and polymyxins have a strong in vitro anti-
microbial activity against ESBL-producing bacteria, and
the first should be considered a reasonable alternative.
This is particularly true from an epidemiological point
of view; in fact today any large hospital should imple-
ment carbapenems-sparing stewardship programs to
control the spread of carbapenemase producing gram
negative bacteria.
Although in the prospective French survey by Mon-
travers and coll, a higher percentage of isolation of
Enterococcus faecalis in non surviving patients was
reported (23% versus 9%) [35], empirical treatment
against Enterococci and has not been generally recom-
mended for patients with community-acquired IAI. In
fact in several clinical trials comparing different thera-
peutic options inclusion/exclusion of agents with
enterococcal coverage provides no impact in outcomes
for patients with community-acquired infections
[178,179].
In the setting of community acquired IAIs, antimicro-
bial therapy for enterococci should be considered on a
patient-by-patient basis, mainly in high risk patients, in
immunocompromised patients and in patients with valv-
ular heart disease or prosthetic materials [180].
Methicillin resistant Staphylococcus aureus (MRSA) is
not commonly isolated from patients with community-
acquired intra-abdominal infection. Therefore empirical
treatment against MRSA is not recommended in this
setting.
Normally empiric antifungal therapy for Candida is
not recommended for adult and pediatric patients with
community acquired intra-abdominal infection with the
exclusion of immunocompromised patients (because of
neutropenia, and receipt of immunosuppressive agents,
including glucocorticosteroids, chemotherapeutic agents,
and immunomodulators) and in patients recently
exposed to broad spectrum antimicrobials. However,
considering the aforementioned high morality rate of
candida peritonitis [38], considering an antifungal cover-
age in critically ill patients should be correct.
Community-acquired IAIs may be managed with
either single or multiple antimicrobial regimens, in rela-
tion to the need to ensure a spectrum of antimicrobial
activity more or less wide.
Beta-lactam/beta-lactamase inhibitor combinations
have an in vitro activity against gram-positive, gram-
negative and anaerobe organisms [181,182] and are still
reliable option for the empiric treatment of IAIs [183].
However, the increasing resistance of Enterobacteriaceae
reported in the last decade also among community-
acquired infections restricts their empirical use to
patients without risk factor for resistances [184].
In the past Cephalosporins have been often used in
the treatment of intra-abdominal infections. Among
third generation cephalosporins both subgroups with
poor activity against Pseudomonas aeruginosa and with
activity against Pseudomonas aeruginosa (cefepime and
ceftazidime) have been used in the treatment of IAIs in
association with metronidazole. Both cephalosporins
have acquired resistance in enterobacteriaceae and
intrinsic resistance in Enterococci [185-188]. In light of
the emerging concern of ESBL producing enterobacter-
iaceae species due to selection pressure by increase use
of cephalosporins, the routinely use of all cephalosporins
should be discouraged.
Aztreonam is a parenteral synthetic beta-lactam anti-
biotic and the first monobactam to be marketed.
Aztreonam exhibits potent and specific activity in vitro
against a wide spectrum of Gram-negative aerobic
pathogens including Pseudomonas aeruginosa but its use
is burdened by the same problems of resistances to
cephalosporins.
Carbapenems have a spectrum of antimicrobial activity
that includes Gram-positives (except MDR resistant gram
positive cocci) and Gram-negative aerobic and anaerobic
pathogens. They are the preferred antimicrobial agents for
ESBL and AmpC-producing organisms; however, their
widespread use in outbreaks and endemic regions of these
organisms has led to increased rates of carbapenem-resis-
tant P. aeruginosa and Acinetobacter sp. In addition, the
selection of intrinsically carbapenem-resistant organisms
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such as Stenotrophomonas maltophilia and vancomycin-
resistant Enterococcus faecium can be seen [189].
Group 1 carbapenems includes ertapenem, a once a
day carbapenem that shares the activity of imipenem
and meropenem against most species, including
extended-spectrum beta-lactamase (ESBL) - producing
pathogens, but is not active against Pseudomonas spp.
and Enterococcus [190,191].
Group 2 includes imipenem/cilastatin, meropenem and
doripenem, that share activity against non-fermentative
gram-negative bacilli. Slightly higher in-vitro activity
against some strains of Pseudomonas sp. has been
reported with doripenem in registrative trials [192].
Also fluoroquinolones have been widely used in the
last years for the treatment of IAIs, because of their
excellent activity against aerobic Gram-negative bacteria
and tissue penetration. In addition all the fluoroquino-
lones are rapidly and almost completely absorbed from
the gastrointestinal tract [193,194]. The combination of
ciprofloxacin/metronidazole has been one of the most
commonly used regimens for the treatment of patients
with complicated IAIs in the last years. The last quino-
lone developed, Moxifloxacin, has shown activity against
a wide range of aerobic Gram-positive and Gram-nega-
tive [195]. Compared with ciprofloxacin, moxifloxacin
has enhanced activity against Gram-positive bacteria
with a decrease in activity against Gram-negative bac-
teria [196]. Among quinolones moxifloxacin seems to be
effective also against Bacterioides fragilis, suggesting that
it may be effective without antianaerobic agents
[197-199].
However, in recent years, the prevalence of resistance
between Enterobacteriaceae and non-fermentative gram-
negative bacilli has been so high as to make their use in
empirical regimen not recommended.
Aminoglycosides are particularly active against aerobic
Gram-negative bacteria and act synergistically against
certain Gram-positive organisms. They are effective
against Pseudomonas aeruginosa but not effective
against anaerobic bacteria. The aminoglycosides may
not be optimal for-the treatment of abscesses or intra-
abdominal infections due to their low penetration in
acidic environments [200]. Therefore they are not
recommended for the routine empiric treatment of
community-acquired IAIs and may be reserved for
patients with allergies to b-lactam agents [1].
Tigecycline is a parenteral glycylcycline antibiotic
derived from minocycline. It is the first representative of
the glycylcycline class of antibacterial agents to be mar-
keted for clinical use [201,202]. Tigecycline has no activ-
ity in vitro against P. aeruginosa and P. mirabilis but
represents a significant treatment option for complicated
IAIs due to its favorable in vitro activity against anaero-
bic organisms, Enterococci, several ESBL-producing
Enterobacteriaceae and carbapenemase-producing Enter-
obacteriaceae, Acinetobacter sp. and Stenotrophomonas
maltophilia [203-206].
The use of tigecycline in the abdominal infections is
particularly attractive in view of its pharmacokinetics/
pharmacodynamics properties. In fact the drug is elimi-
nated by active biliary secretion, able to determinate
very high biliary and fecal concentrations [207]. A study
finalized to the determination of tissue and correspond-
ing serum concentration of tigecycline at selected time
points in several different body sites, performed in 104
subjects undergoing surgical or medical procedures,
showed that concentration, expressed as the ratio of
AUC0-24 was extremely high for bile [208].
Moreover a PD analysis based on the data of micro-
biological surveys, performed by the Montecarlo simula-
tion, demonstrated a predicted cumulative response
(PCR) fraction for Tigeciclyne in peritonitis over 95%
for E. coli and Enterococcus and over 75% for Klebsiella
spp, Enterobacter spp and A. baumannii [209]. Tigecy-
cline (TGC) has demonstrated non-inferiority in terms
of clinical efficacy and safety versus imipenem/cilastatin
and combination regimen of Ceftriaxone/metronidazole
in Phase 3 clinical trials for complicated intra-abdominal
infection [210,211].
But the greater significance of the use of tigecycline in
empirical antibiotic regimens for IAIs is related to the
possibility of saving carbapenems prescriptions. From an
epidemiological point of view tigecycline should be a
qualified therapeutic option in a carbapenems-sparing
stewardship programs, as extended-spectrum b-lacta-
mases become widely disseminated among the endogen-
ous gut Enterobacteriaceae.
Distinguishing antimicrobial regimens according to the
clinical patient’s severity, the presumed pathogens and
risk factors for major resistance patterns, the presumed/
identified source of infection it is possible to standardize
the empirical approach to the main clinical condition
related to IAIs.
In appendices 1, 2, 3, 4 are summarized the antimicro-
bial regimens for extrabiliary community-acquired IAIs,
recommended by WSES consensus conference.
Since the causative pathogens and the related resis-
tance patterns can not easily be predicted (higher-
risk patients), cultures from the site of infection
must be always obtained (Recommendation 1 B).
Although the absence of impact of bacteriological cul-
tures has been documented, especially in appendicitis, in
this era of the broad spread of resistant microorganisms
such as nosocomial and community extended-spectrum
b-lactamase (ESBL) Enterobacteriaceae, carbapenemase
producing gram negatives, b lactam- and vancomycin
resistant enterococci (VRE), the threat of resistance is a
source of major concern for clinicians. Therefore the
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results of the microbiological analyses have great impor-
tance for the therapeutic strategy of every patient, in
particular in the adaptation of the initial antibiotic treat-
ment, and at the same time are of paramount impor-
tance to ensure adequacy of empirical antimicrobial
treatment.
The habit of considering the microbiological diagnosis
useless is probably responsible for the relative scarcity of
microbiological data and the variability of results of the
few studies appropriate to emphasize the changes in
resistance in IAI patients.
Cultures should be performed at least from intra-
abdominal samples from surgery or interventional drai-
nage procedures, providing sufficient volume (at least
1 mL of fluid or tissue, preferably more) and sending
them to the laboratory using an appropriate transport
system.
Biliary Community-Acquired Intra-Abdominal
infections
Source control
Recent guidelines have been published for the manage-
ment of acute cholecystitis and acute cholangitis
[212-214].
Cholecystitis
Laparoscopic cholecystectomy has been accepted as
an effective and safe treatment for acute cholecystitis
(Recommendation 1 A).
Laparoscopic cholecystectomy versus open cholecys-
tectomy question has been extensively investigated.
Beginning in the early 1990s, techniques and indications
for laparoscopic management of the acutely inflamed
gallbladder were discussed and laparoscopic cholecys-
tectomy is now accepted as being safe for acute
cholecystitis.
Many RCTs have demonstrated that laparoscopic cho-
lecystectomy is effective and safe for acute cholecystitis
[215-220].
In the Johansson and coll. randomized clinical trial
there were no significant differences beetwen laparo-
scopic cholecystectomy and open cholecystectomy, in
rate of postoperative complications, pain score at dis-
charge and sick leave.
Seventy patients who met the criteria for acute cho-
lecystitis were randomized to open or laparoscopic
cholecystectomy. In eight patients a laparoscopic pro-
cedure was converted to open cholecystectomy. Med-
ian operating time was 90 (range 30-155) and 80
(range 50-170) min in the laparoscopic and open
groups respectively (P = 0.040). The direct medical
costs were equivalent in the two groups. Although
median postoperative hospital stay was 2 days in each
group, it was significantly shorter in the laparoscopic
group (P = 0.011).
In the Kiviluoto and coll. randomized clinical trial
there were no deaths or bile-duct lesions in either
group, but the postoperative complication rate was sig-
nificantly (p = 0.0048) higher in the open cholecystect-
omy than in the laparoscopic cholecystectomy group:
seven (23%) patients had major and six (19%) minor
complications after OC, whereas only one (3%) minor
complication occurred after LC. The postoperative hos-
pital stay was significantly shorter in the LC than the
OC group (p = 0.0063).
Early laparoscopic cholecystectomy during acute
cholecystitis appears safe and shortens the total hos-
pital stay when it is compared with delayed laparo-
scopic cholecystectomy (Recommendation 1 A).
The most important innovation in the surgical treat-
ment of acute gallstone cholecystitis (AGC) concerns
timing.
Several RCTs and meta-analyses [221-224] have
showed that, compared with delayed laparoscopic chole-
cystectomy, early laparoscopic cholecystectomy for acute
cholecystitis reduces the total length of hospital stay and
the risk of readmissions attributable to recurrent acute
cholecystitis. It is a more cost-effective approach for the
management of acute cholecystitis.
In the Gurusamy and coll. meta-analysis [221] there
was no significant difference between early and delayed
groups in terms of bile duct injury or conversion to
open cholecystectomy. The total hospital stay was
shorter by 4 days for early laparoscopic cholecystectomy.
In Siddiqui and coll. meta-analysis [222] there was no
significant difference in conversion rates and postopera-
tive complications between early and delayed groups.
Operation time was significantly reduced with delayed
cholecystectomy. The total hospital stay was significantly
reduced with early cholecystectomy.
In order to analyze whether delay from onset of symp-
toms was related to the conversion rate in patients with
a acute cholecystitis, a retrospective case note review of
patients undergoing emergency cholecystectomy in a
single institution between January 2002 and December
2005 was published on 2007 [225]. Early intervention
for acute cholecystitis (preferably within 2 days of onset
of symptoms) was most likely to result in successful
laparoscopic cholecystectomy; increasing delay was asso-
ciated with conversion to open surgery.
The use of percutaneous cholecystostomy in criti-
cally ill patients with acute cholecystitis is both safe
and effective (Recommendation 2 B).
There are no randomized studies evaluating the
outcome of percutaneous cholecystostomy vs. cholecys-
tectomy. It is not possible to make definitive recommen-
dations regarding treatment by PC or cholecystectomy
in elderly or critically ill patients with acute cholecystitis.
The use of percutaneous cholecystostomy in critically ill
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patients with acute cholecystitis is both safe and
effective.
Whenever possible, percutaneous cholecystostomy
should be followed by laparoscopic cholecystectomy.
A systematic electronic database search was performed
on the subject of percutaneous cholecystostomy (PC) in
the elderly population [226].
Successful intervention was seen in 85.6% of patients
with acute cholecystitis. A total of 40% of patients trea-
ted with PC were later cholecystectomized, with a mor-
tality rate of 1.96%. Procedure mortality was 0.36%, but
30-day mortality rates were 15.4% in patients treated
with PC and 4.5% in those treated with acute cholecys-
tectomy (P < 0.001).
Early diagnosis of gallbladder perforation and
immediate surgical intervention may decrease mor-
bidity and mortality (Recommendation 1 C).
Gallbladder perforation is an unusual initial presenta-
tion of gallbladder disease. Early diagnosis of gallbladder
perforation and immediate surgical intervention are of
prime importance in decreasing morbidity and mortality
associated with this condition.
It is rarely diagnosed preoperatively. Late operative
intervention is associated with increased morbidity,
mortality, number of ICU admissions, and long post-
operative hospital stays [227-230].
Cholangitis
Biliary drainage is a radical method to relieve cholesta-
sis, a cause of acute cholangitis, and takes a central part
in the treatment of acute cholangitis.
Biliary drainage can be achieved by three different
procedures:
• Endoscopic
• Percutaneous transhepatic
• Open drainage
It has been reported that when no appropriate biliary
drainage was available 20-30 years ago, the mortality of
acute cholangitis with conservative treatment was extre-
mely high. There has been no randomized controlled
trial (RCT) comparing conservative treatment and bili-
ary drainage. However, many patients with acute cholan-
gitis cannot be treated by conservative treatment alone
[231,232].
Endoscopic drainage is safer and more effective
than open drainage. (Recommendation 1 A).
A randomized controlled trial (RCT) was conducted to
compare endoscopic and open drainage in 82 patients
with severe acute cholangitis with hypotension and dis-
turbed consciousness. This RCT demonstrated that the
morbidity and mortality of endoscopic naso-biliary drai-
nage (ENBD) + endoscopic sphincterotomy (EST; n =
41) were significantly lower than those of T-tube
drainage under laparotomy (n = 41). The Authors con-
cluded that morbidity and mortality of endoscopic naso-
biliary drainage (ENBD) + endoscopic sphincterotomy
are lower than those of T-tube drainage under laparot-
omy [233].
Endoscopic modalities currently are favored over
percutaneous procedures because of a lower risk of
complication. There is no RCT comparing endoscopic
and percutaneous drainage (Recommendation 2 C).
Considering the rare occurrence of serious complica-
tions such as intraperitoneal hemorrhage and biliary
peritonitis, and the shorter duration of hospitalization,
endoscopic drainage is preferred whenever it is available
and applicable [234-237].
Open drainage should only be used in patients for
whom endoscopic or percutaneous transhepatic drai-
nage is contraindicated or those in whom it has been
unsuccessfully performed. (Recommendation 2 C).
There is no RCT comparing open drainage and endo-
scopic or percutaneous drainage [238].
Antimicrobial therapy for biliary infections
Antibiotics are always recommended in complicated
cholecystitis and in delayed treatment of uncomplicated
cholecystitis.
In uncomplicated cholecystitis, when the focus of
infection is treated effectively by cholecystectomy, the
administration of antibiotics is unnecessary beyond
prophylaxis.
Patients with an infected focus that can be eradicated
effectively by surgical intervention can potentially be
treated with only 24 hours of antimicrobial prophylaxis.
The most important factors for antimicrobial drug
selection in biliary infections are antimicrobial activ-
ity against causative bacteria, clinical patient’s condi-
tion and biliary levels of the antimicrobial agents
(Recommendation 1 B).
Knowledge of the secretion of antibiotics into bile
and of their efficacy should be helpful in choosing
the best therapeutic regimen (Recommendation 1 C).
Organisms most often isolated in biliary infections are
the gram-negative aerobes, Escherichia coli and Kleb-
siella pneumonia and anaerobes, especially Bacteroides
fragilis. Activity against enterococci is not required since
their pathogenicity in biliary tract infections remains
unclear [239-241].
The efficacy of antibiotics in the treatment of biliary
infections depends on effective biliary antibiotic concen-
trations [242-245].
It has been debated whether antimicrobials with good
biliary penetration should be recommended for biliary
infections. However, there are no clinical or experimen-
tal data to strongly support the recommendation of
antimicrobials with excellent biliary penetration for
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these patients. Other important factors include the anti-
microbial potency of individual compounds, and the
effect of bile on antibacterial activity [246].
Penicillins are still frequently used in biliary infections.
Aminopenicillins such as amoxicillin are excreted
unchanged in the bile. In patients with normal function
of biliary tract, amoxicillin bile concentrations are higher
than the serum concentrations (3 rates higher than the
concentrations in plasma).
Fluoroquinolones have excellent bioavailability; they
are excreted by renal, hepatic and biliary excretion.
Ciprofloxacin biliary concentrations are generally higher
then the concentrations in the plasma (28 to 45 rates
higher than the concentrations in plasma). Besides,
ciprofloxacin has been proven to reach high biliary con-
centrations also in patients with obstruction due to the
anticipated secretion of quinolone by biliary epithelium.
An alternative to amoxicillin/clavulanate, ciprofloxacin
plus metronidazole may be indicated for biliary infec-
tions, in no critically ill patient and in absence of risk
factors for resistance patterns.
Piperacillin is the penicillin with highest rate of bile
excretion (25% in active form). Bile concentrations are
up to 60 rates higher than the concentrations in plasma.
The combination of piperacillin with tazobactam further
extends its spectrum. However tazobactam pharmacoki-
netics is different from piperacillin pharmacokinetics
and during a regular therapy regimen employing pipera-
cillin/tazobactam combination, tazobactam reaches
effective concentrations in the bile only during the first
3 hours following its administration.
Glicilcyclines such as tigecycline have a broad spec-
trum of activity and a very good availability in the blad-
der wall and bile. Tigecycline is a very good
antimicrobial option in biliary infections.
Also for biliary intra-abdominal infections WSES con-
sensus conference distinguished antimicrobial regimens
according to the clinical patient’s condition and the risk
factors for resistance patterns.
In appendices 5, 6, 7, 8 are summarized the antimicro-
bial regimens for biliary community-acquired intra-
abdominal infections, recommended by WSES consen-
sus conference.
Hospital-acquired intra-abdominal infections
Hospital-acquired intra-abdominal infections are infec-
tions not present on admission that become evident 48
hours or more after admission in patients hospitalized
for a reason other than intra-abdominal infection [247].
Both post-operative and non post-operative nosoco-
mial intra-abdominal infections are associated with
increased mortality due to underlying patient health sta-
tus and increased likelihood of infection caused by
MDR organisms [248-255].
The main clinical differences between the patients
with community-acquired intra-abdominal infections
and patients with nosocomial intra-abdominal infections
are [35]:
• higher proportion of underlying disease
• severity criteria at the time of diagnosis for noso-
comial cases
The most common cause of postoperative peritonitis
is anastomotic failure/leak.
In few instances of postoperative peritonitis, the ana-
stomosis may be intact; however, the patient may
remain sick because of residual peritonitis. Among them
is the inadequate drainage of the initial septic focus, in
which the surgeon failed to drain completely, or more
commonly, the peritoneum does not have the sufficient
defense capacity to control the problem.
Hospital acquired, non-postoperative IAIs, which arise
in patients hospitalized for reasons unrelated to abdom-
inal pathology, portend a particularly poor prognosis.
Diagnosis is often delayed due to both a low index of
suspicion, poor underlying health status, and altered
sensorium.
Non-postoperative nosocomial intra-abdominal infec-
tions are frequently characterized as severe infections
diagnosed lately in fragile patients [254].
Prospective analysis of patients operated for secondary
non-postoperative nosocomial intra-abdominal infec-
tions collected in 176 French study centers was pub-
lished 2004 [254].
When compared with CAI patients, Non-PostopNAI
patients presented:
• increased interval between admission to the surgi-
cal ward and operation
• increased proportions of underlying diseases
In non-PostopNAI patients, increased proportions of
therapeutic failure and of fatalities were observed [254].
Unlike previous studies, recent studies observed no
difference in incidence of prognosis between commu-
nity-acquired and nosocomial intra-abdominal
infections.
Riché and coll. [45] have prospectively studied a
cohort of 180 consecutive patients operated on for gen-
eralized peritonitis.
There were 24 deaths among the 112 patients with
community-acquired peritonitis (21% mortality rate) and
11 deaths among the 68 patients with postoperative
peritonitis (16% mortality rate). Survival rates at day 30
were not statistically different for community-acquired
and postoperative peritonitis. The proportion of patients
operated less than 24 hours after the onset of symptoms
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was not different between community-acquired and
postoperative peritonitis (54% vs. 49%, respectively; P =
0.61).
In the Inui and coll. [256] study, 452 patients, 234
(51.8%) had CIAIs and 218 (48.2%) had NIAIs, treated
at a single urban academic hospital over 8 years (June
1999-June 2007) were retrospectively reviewed.
When patients with appendicitis were excluded, there
was no difference in mortality or complications between
patients with CIAIs and NIAIs.
Source control represents a key component of success
in therapy of sepsis. It includes drainage of infected
fluids, debridement of infected soft tissues, removal of
infected devices or foreign bodies, and finally, definite
measures to correct anatomic derangement resulting in
ongoing microbial contamination and to restore optimal
function.
Recommendations have low grade due to the difficulty
to perform appropriate randomized clinical trials in this
respect.
Percutaneous abscess drainage should be the pri-
mary procedure to treat postoperative localized
intra-abdominal abscess without signs of generalized
peritonitis (Recommendation 2 C).
Some retrospective studies in the surgery and radiol-
ogy literature have documented the effectiveness of per-
cutaneous drainage to treat postoperative localized
intra-abdominal abscess [257-259].
Source control should be obtained as early as pos-
sible after the diagnosis of postoperative intra-
abdominal peritonitis has been confirmed. Inability
to control the septic source is associated significantly
with increase in mortality (Recommendation 1 C).
Inability to control the septic source is associated sig-
nificantly with increase in mortality.
Delaying relaparotomy for more than 24 h or the pre-
sence of organ failure result in higher mortality in post-
operative intra-abdominal infections.
The value of physical tests and laboratory parameters
in diagnosing abdominal sepsis is limited. CT-scanning
revealed the highest diagnostic accuracy. Early relaparot-
omy appears to be the most reasonable option to treat
postoperative peritonitis [260].
Re-laparotomy strategy
Some patients are prone to persisting intra-abdominal
infection regardless of eradication of the source of infec-
tion and timely relaparotomy provides the only surgical
option that significantly improves outcome.
In these cases single operation may not be sufficient
to achieve source control, thus re-exploration is neces-
sary [261-263].
The decision to and when to perform a relaparotomy
in secondary peritonitis is largely subjective and based
on professional experience. Factors indicative of pro-
gressive or persistent organ failure during early post-
operative follow-up are the best indicators for ongoing
infection and associated positive findings at relaparot-
omy [264-266].
Three methods of local mechanical management of
abdominal sepsis following initial laparotomy for source
control are currently debated:
(1) Open-abdomen
(2) planned relaparotomy
(3) on-demand relaparotomy
On demand relaparotomy may be considered the
preferred surgical strategy in patients with severe
peritonitis because it has a substantial reduction in
relaparotomies, health care utilization, and medical
costs. (Recommendation 1 A)
In 2007 van Ruler and coll. [267] published a rando-
mized, clinical trial comparing on-Demand Vs Planned
Relaparotomy strategy in patients with severe peritonitis.
In the van Ruler trial a total of 232 patients with
severe intra-abdominal infections (116 on-demand and
116 planned) were randomized.
In planned relaparotomy group, relaparotomies were
performed every 36 to 48 hours after the index laparot-
omy to inspect, drain, lavage, and perform other neces-
sary abdominal interventions for residual peritonitis or
new infectious focus.
In on-Demand relaparotomy group, relaparotomies
were only performed in patients with clinical deteriora-
tion or lack of clinical improvement with a likely intra-
abdominal cause.
Patients in the on-demand relaparotomy group did
not have a significantly lower rate of adverse outcomes
compared with patients in the planned relaparotomy
group but did have a substantial reduction in relaparo-
tomies, health care utilization, and medical costs.
Patients in the on-demand group had shorter median
intensive care unit stays (7 vs 11 days; P = .001) and
shorter median hospital stays (27 vs 35 days; P = .008).
Direct medical costs per patient were reduced by 23%
using the on-demand strategy.
Some studies have investigated open abdomen in
intra-abdominal infections and generated great interest
and hope [268-270].
In 2007 a randomized study by Robledo and coll.
[271] compared open with closed “on demand” manage-
ment of severe peritonitis.
During a 24-month period, 40 patients with SSP were
admitted for treatment. Although the difference in the
mortality rate (55% vs. 30%) did not reach statistical sig-
nificance (p < 0.05; chi-square and Fisher exact test), the
relative risk and odds ratio for death were 1.83 and 2.85
times higher in open abdomen patients group. This clin-
ical finding, as evidenced by the clear tendency toward a
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more favorable outcome for patients in closed open
group, led to termination of the study at the first
interim analysis.
This randomized study from a single institution
demonstrates that closed management of the abdomen
may be a more rational approach after operative treat-
ment of SSP and questions the recent enthusiasm for the
open alternative, which has been based on observational
studies. However in this study, the “open abdomen” was
managed with a non-absorbable polypropylene mesh,
without topical negative pressure.
Antimicrobial treatment of hospital-acquired intra-
abdominal infections
Hospital-acquired IAIs are among the most difficult
infections to diagnose early and treat effectively.
A successful outcome depends on early diagnosis,
rapid and appropriate surgical intervention, and the
selection of effective antimicrobial regimens.
Hospital acquired infections are commonly caused
by larger and more resistant flora, and for these
infections, complex multidrug regimens are always
recommended (Recommendation 1 B).
The threat of antimicrobial resistance has been identi-
fied as one of the major challenges in the management
of complicated IAIs and was already discussed in the
previous chapter.
In order to describe the differences in microbiological
and resistance patterns between community-acquired
and nosocomial intra-abdominal infections a prospec-
tive, observational multicentric study (EBIIA) was com-
pleted in French [35]. From January to July 2005,
patients undergoing surgery/interventional drainage for
IAIs with a positive microbiological culture were
included by 25 French centers. A total of 829 microor-
ganisms were cultured.
In this study the number of peritoneal microorganisms
per sample was ≥3 in 34% and 54% of cases, respectively,
for community-acquired and nosocomial infections (P <
0.001). The distribution of the microorganisms differed
according to the nosocomial or community origin of the
infection but not according to their location (data not
shown). In nosocomial patients, increased proportions of
Enterococcus faecalis (33% versus 19% in community-
acquired patients; P < 0.05) and Pseudomonas aeruginosa
strains (13% versus 5% in community-acquired patients;
P < 0.01) were observed. Conversely, in nosocomial
patients, decreased proportions of Escherichia coli (52%
versus 72% in community-acquired patients, P < 0.001)
and streptococci strains were reported (31% versus 50%
in community-acquired patients, P < 0.01).
Therefore the inclusion of anti-enterococcal drugs in
any empirical antibiotic regimens in severe nosocomial
IAIs and/or in patients with well known risk factors,
seems appropriate, mainly if directed against E. faecalis.
Empiric therapy directed against vancomycin-resistant
Enterococcus faecium is not recommended unless the
patient is at very high risk for an infection due to this
organism, such as a liver transplant recipient with an
intra-abdominal infection originating in the hepatobili-
ary tree or a patient known to be colonized with vanco-
mycin-resistant E. faecium.
Enterococcus infections are difficult to treat because of
both intrinsic and acquired resistance to many
antibiotics.
Enterococci are intrinsically resistant to many penicil-
lins, and all cephalosporins with the possible exception
of ceftobiprole and ceftaroline, currently undergoing
clinical evaluation. Besides Enterococci have acquired
resistance to many other classes of antibiotics, to which
the organisms are not intrinsically resistant, including
fluoroquinolones, aminoglycosides, and penicillins.
Many strains of E. faecalis are susceptible to certain
penicillins and glycopeptides; however, some strains of
E. faecium may be resistant to these agents [272].
Vancomycin-resistant Enterococcus (VRE) infections
have been associated with increased morbidity and mor-
tality [273,274].
Many factors can increase the risk of colonization with
VRE. These include previous antibiotic therapy (the
number and duration of antibiotics received) prolonged
hospitalization, hospitalization in an intensive care unit
severity of illness, invasive procedures and devices, gas-
trointestinal surgery, transplantation, proximity to
another VRE-positive patient [275].
Affected patients usually have multiple and relevant
co-morbidities, with prolonged hospital stay and
received long courses of broad spectrum antibiotics.
In the survey of Montravers and coworkers no differ-
ences in frequency of isolation of Candida spp were
identified in community or hospital acquired IAIs, and
the overall prevalence was under 5%, in contrast with
other observations, especially those related to patients
with recurrent gastrointestinal perforation/anastomotic
leakage [276,277].
Although the epidemiological role of Candida spp in
nosocomial peritonitis is not yet defined, the clinical
role is significant, because Candidal isolation is normally
associated to a poor prognosis.
The same study group on 2006 published an elegant
retrospective, case-control study conducted in critically
ill patients admitted to 17 French ICUs where the yield-
ing of Candida spp from peritoneal specimen was a vari-
able independently associated to mortality in the setting
of nosocomial peritonitis [37].
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More recently Montravers and coll. reported a mortal-
ity rate of 38% in a prospective cohort of 93 patients
admitted to ICU with candidal peritonitis [38].
Therefore, like for Enterococci, the inclusion of an
anticandidal drug in the empiric regimen of severe
nosocomial acquired IAIs, seems appropriate as con-
firmed by IDSA guidelines [1].
The recently published IDSA guidelines for the treat-
ment of invasive candidiasis [278] don’t comprise a chap-
ter specifically dedicated to candidal peritonitis. However
the expert panels generically favor the use of echinocan-
dins as first line empirical therapy in severely ill patients,
recommending fluconazole for less severe conditions.
Therefore, transferring this concept to the context of
IAIs we might advise the proscription of echinocandins
as first line treatment in severe nosocomial IAIs. The
IDSA guidelines also recommend the transition from an
echinocandin to fluconazole for patients clinically stable
and who have isolates of Candida spp susceptible to flu-
conazole; so the final recommendation would be to start
with an echinocandin and to de-escalate to fluconazole
as soon as possible on a clinical or microbiological basis.
In appendices 9,10 are summarized the antimicrobial
regimens for hospital-acquired intra-abdominal infec-
tions, recommended by WSES consensus conference.
Conclusions
The timing and adequacy of source control is the most
important issue in the management of intra-abdominal
sepsis, because an inadequate and late operation may
have a negative effect on the outcome.
Concomitant adequate empiric antimicrobial therapy
further influences patients’ morbidity and mortality.
Inappropriate antibiotic therapy of intra-abdominal
infections may result in poor patient outcome and the
selection of an appropriate agent is a real challenge
because of the emerging resistance of target organisms
to commonly prescribed antibiotics.
It is demonstrated that a strategy of early goal-direc-
ted therapy decreases the in-hospital mortality of
patients who are taken to the emergency department in
septic shock. An organized approach to the haemody-
namic support to sepsis includes use of fluid resuscita-
tion, vasopressor therapy and inotropic therapy.
A multidisciplinary approach to the management of
critically ill patients may be an important factor in the
quality of care.
Appendices
Appendix 1. Antimicrobial therapy for community-
acquired extrabiliary IAI in no critically ill patient, in
absence of risk factors for ESBL
Community-acquired extrabiliary IAI
No critically ill patient
No risk factors for ESBL
AMOXICILLIN/CLAVULANATE
Daily schedula: 2.2 g every 6 hours (Infusion time
2 hours)
OR (Allergy to beta-lactams):
CIPROFLOXACIN
Daily schedula: 400 mg every 8 hours (Infusion time
30 min)
+
METRONIDAZOLE
Daily schedula: 500 mg every 6 hours (Infusion time
1 hour)
Appendix 2. Antimicrobial therapy for community-
acquired extrabiliary IAI in no critically ill patient, in
presence of risk factors for ESBL
Community-acquired extrabiliary IAI
No critically ill patient
Risk factors for ESBL
ERTAPENEM
Daily schedula: 1 g every 24 hours (Infusion time
2 hours)
OR
TIGECYCLINE
Daily schedula: 100 mg LD then 50 mg every 24 hours
(Infusion time 2 hours)
Appendix 3. Antimicrobial therapy for community-
acquired extrabiliary IAI in critically ill patient, in absence
of risk factors for ESBL
Community-acquired extrabiliary IAI
Critically ill patient (± SEVERE SEPSIS)
No risk factors for ESBL
PIPERACILLIN/TAZOBACTAM
Daily schedula: 8/2 g LD then 16/2 g/die by continu-
ous infusion or
4.5 g every 6 hours (infusion time 4 hours)
Appendix 4. Antimicrobial therapy for community-
acquired extrabiliary IAI in critically ill patient, in
presence of risk factors for ESBL
Community-acquired IAI
Critically ill patient (± SEVERE SEPSIS)
Risk factors for ESBL
MEROPENEM
Daily schedula: 500 mg every 6 hours (Infusion time
6 hours)
OR
IMIPENEM
Daily schedula: 500 mg every 4 hours (Infusion time
3 hours)
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+/-
FLUCONAZOLE
Daily schedula: 600 mg LD then 400 mg every
24 hours (Infusion time 2 hours)
Appendix 5. Antimicrobial therapy for biliary IAI in no
critically ill patient, in absence of risk factors for ESBL
Community-acquired biliary IAI
No critically ill patient
No risk factors for ESBL
AMOXICILLIN/CLAVULANATE
Daily schedula: 2.2 g every 6 hours (Infusion time
2 hours)
OR (Allergy to beta-lactams)
CIPROFLOXACIN
Daily schedula: 400 mg every 8 hours (Infusion time
30 min)
+
METRONIDAZOLE
Daily schedula: 500 mg every 6 hours (Infusion time
1 hour)
Appendix 6. Antimicrobial therapy for biliary IAI in no
critically ill patient, in presence of risk factors for ESBL
Community-acquired biliary IAI
No critically ill patient
Risk factors for ESBL
TIGECYCLINE
Daily schedula: 100 mg LD then 50 mg every 12 hours
(Infusion time 2 hours)
Appendix 7. Antimicrobial therapy for biliary IAI in
critically ill patient, in absence of risk factors for ESBL
Community-acquired biliary IAI
Critically ill patient (± SEVERE SEPSIS)
No risk factors for ESBL
PIPERACILLIN/TAZOBACTAM
Daily schedula: 8/2 g LD then 16/2 g/die by continu-
ous infusion or
4.5 g every 6 hours (infusion time 4 hours)
Appendix 8. Antimicrobial therapy for biliary IAI in
critically ill patient, in presence of risk factors for ESBL
Community-acquired biliary IAI
Critically ill patient (SEVERE SEPSIS)
Risk factors for ESBL
PIPERACILLIN
Daily schedula: 8 g by LD then 16 g by continuous
infusion or
4 g every 6 hours (Infusion time 4 hours)
+
TIGECYCLINE
Daily schedula: 100 mg LD then 50 mg every 12 hours
(Infusion time 2 hours)
+/-
FLUCONAZOLE
Daily schedula: 600 mg LD then 400 mg every
24 hours (Infusion time 2 hours)
Appendix 9. Antimicrobial therapy for hospital-acquired
IAI in no critically ill patient
Hospital acquired IAI
No critically ill patient (< SEVERE SEPSIS)
Risk factors for MDR pathogens
PIPERACILLIN
Daily schedula: 8 g by LD then 16 g by continuous
infusion or
4 g every 6 hours (Infusion time 4 hours)
+
TIGECYCLINE
Daily schedula: 100 mg LD then 50 mg every 12 h
(Infusion Time: 2 hours)
+
FLUCONAZOLE
Daily Schedula: 600 mg LD then 400 mg every 24 h
(Infusion time: 2 hours)
Appendix 10. Antimicrobial therapy for hospital-acquired
IAI in critically ill patient
Hospital-acquired extrabiliary IAI
Critically ill patient (±SEVERE SEPSIS)
Risk factors for MDR pathogens
PIPERACILLIN
Daily schedula: 8 g by LD then 16 g by continuous
infusion or
4 g every 6 hours (Infusion time 4 hours)
+
TIGECYCLINE
Daily schedula: 100 mg LD then 50 mg every 12 h
(Infusion Time: 2 hours)
+
ECHINOCANDIN
caspofungin (loading dose of 70 mg, then 50 mg
daily),
anidulafungin (loading dose of 200 mg, then 100 mg daily),
micafungin (100 mg daily)
OR
MEROPENEM
Daily Schedula: 500 mg every 6 h (Infusion time:
6 hours)
IMIPENEM
Daily Schedula: 500 mg every 4 h (Infusion time:
3 hours)
DORIPENEM
Daily Schedula: 500 mg every 8 h (Infusion time:
4 hours)
+
TEICOPLANIN
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Daily Schedula: LD 12 mg/kg/12 h for 3 doses then 6
mg/kg every 12 h (with TDM corrections - PD target
20-30 mg/L)
Daily schedula: 16 g by continuous infusion or
4 g every 6 hours (infusion time 4 hours)
+
ECHINOCANDIN
caspofungin (loading dose of 70 mg, then 50 mg
daily),
anidulafungin (loading dose of 200 mg, then 100 mg
daily),
micafungin (100 mg daily)
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